The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Talquetamab treatment in patients with R/R myeloma with prior exposure to T-cell-directed therapies
Allison Graeter, MD, Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the overall response rate (ORR) seen with talquetamab in patients with relapsed/refractory (R/R) multiple myeloma (MM) with prior exposure to T-cell-directed therapies, highlighting that the ORR is higher in patients with prior CAR-T exposure than in those treated with bispecific antibodies. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
